title: 99mTc-3PRGD2 for integrin receptor imaging of lung cancer: a multicenter study.
abstract: (99m)Tc-3PRGD2 is a new SPECT tracer targeting integrin α(V)β(3) receptor for detecting tumors, imaging angiogenesis, and evaluating tumor response to therapy. A multicenter study was designed to investigate the efficacy of (99m)Tc-3PRGD2 for the evaluation of patients with lung cancer.
  
  
  METHODS
  Seventy patients (51 men, 19 women; mean age ± SD, 63 ± 9 y) with a suspected lung lesion and for whom definite pathologic diagnosis was finally obtained (malignant, n = 58; benign, n = 12) were recruited from 6 centers. Whole-body planar scanning and chest SPECT were performed at 1 and 4 h, respectively, after intravenous injection of 11.1 MBq/kg (0.3 mCi/kg) of (99m)Tc-3PRGD2. The images were read in consensus by 6 experienced nuclear medicine physicians masked to the source, history, and pathologic diagnosis. The tumor-to-background (T/B) ratios were calculated for semiquantitative analysis. A Student t test was used for statistical analysis, and a P value less than 0.05 was considered significant.
  
  
  RESULTS
  With low (99m)Tc-3PRGD2 background in the lungs and mediastinum, most lung malignancies were prominent on the 1-h images (T/B ratio, 1.65 ± 0.47 for the planar imaging and 2.78 ± 1.52 for SPECT). The T/B ratios were significantly lower in the benign lesions (P < 0.05). The sensitivity was 88% for semiquantitative analysis and could reach 93%-97% in visual analysis when considering the volume effect, necrosis, and metastasis. However, the specificity was only 58%-67%. Most lymph node and bone metastases could also be detected.
  
  
  CONCLUSIONS
  (99m)Tc-3PRGD2 imaging at 1 h is sensitive for the detection of lung cancer, meriting further investigation of (99m)Tc-3PRGD2 as a novel clinical tracer for integrin receptor imaging.
authors.affiliation: Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
authors.forename: Zhaohui
authors.initials: Z
authors.lastname: Zhu
authors.forename: Weibing
authors.initials: W
authors.lastname: Miao
authors.forename: Qianwei
authors.initials: Q
authors.lastname: Li
authors.forename: Haojie
authors.initials: H
authors.lastname: Dai
authors.forename: Qingjie
authors.initials: Q
authors.lastname: Ma
authors.forename: Feng
authors.initials: F
authors.lastname: Wang
authors.forename: Aiming
authors.initials: A
authors.lastname: Yang
authors.forename: Bing
authors.initials: B
authors.lastname: Jia
authors.forename: Xiaona
authors.initials: X
authors.lastname: Jing
authors.forename: Sha
authors.initials: S
authors.lastname: Liu
authors.forename: Jiyun
authors.initials: J
authors.lastname: Shi
authors.forename: Zhaofei
authors.initials: Z
authors.lastname: Liu
authors.forename: Zhoushe
authors.initials: Z
authors.lastname: Zhao
authors.forename: Fan
authors.initials: F
authors.lastname: Wang
authors.forename: Fang
authors.initials: F
authors.lastname: Li
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D006801:Humans; D039302:Integrin alphaVbeta3 / Q000378:metabolism*; D008175:Lung Neoplasms / Q000000981:diagnostic imaging* / Q000378:metabolism* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D015609:Organotechnetium Compounds / Q000493:pharmacokinetics; D010456:Peptides, Cyclic / Q000493:pharmacokinetics; D015899:Tomography, Emission-Computed, Single-Photon / Q000379:methods*
chemical_list: D039302:Integrin alphaVbeta3; D015609:Organotechnetium Compounds; D010456:Peptides, Cyclic; C561921:technetium 99m (HYNIC-3PRGD(2))(tricine)(TPPTS)